Effectiveness of Pharmacological Treatments in Pediatric Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis - Takeaways - MDSpire

Effectiveness of Pharmacological Treatments in Pediatric Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis

  • By

  • Shehab Yaser

  • Hatem Yaser

  • Hazem E. Mohammed

  • Mohamed Nasser

  • Mohamed Khalafalla Darwish

  • Mohamed E. Haseeb

  • Anas Hussein Heiba

  • Mohamed Mabrouk Ghonaim

  • Heba Aboeldahab

  • Zeyad Bady

  • December 8, 2025

  • 0 min

Share

  • 1

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition in children globally.

  • 2

    The prevalence of MASLD is estimated at 7.6% in the general pediatric population and 34.2% among children in obesity clinics.

  • 3

    Lifestyle modifications remain the cornerstone of MASLD management, but adherence to these changes is often challenging in pediatric patients.

  • 4

    Pharmacologic treatments like vitamin E, metformin, and orlistat show promise, but no universally accepted pharmacologic treatment exists for pediatric MASLD.

  • 5

    This systematic review aims to assess the efficacy and safety of current and emerging treatments for MASLD in children through randomized controlled trials.

Original Source(s)

Effectiveness of Pharmacological Treatments in Pediatric Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis

  • by Shehab Yaser, Hatem Yaser, Hazem E. Mohammed, Mohamed Nasser, Mohamed Khalafalla Darwish, Mohamed E. Haseeb, Anas Hussein Heiba, Mohamed Mabrouk Ghonaim, Heba Aboeldahab, Zeyad Bady

  • December 8, 2025

Related Content

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

Usefulness of ultrasound in diagnosing constipation in children: a narrative review

NLR inflammasome pathways: key targets for pathogenesis and therapy of metabolic diseases